| 초록 |
Triple-negative breast cancer (TNBC) has an aggressive phenotype with lack expression of estrogen receptor, progesterone receptor, and HER2. It does not respond to hormone therapy and conventional chemotherapy. In order to overcome its limitations, we designed targeted therapeutics with Trop2 that was identified cell surface glycoprotein overexpressed in 80% of TNBC patients. anti-Trop2 antibody was induced as targeting ligand to polymeric nanoparticles (TNPs) based on carboxymethyl dextran derivatives with bioreducible disulfide bonds. As anti-cancer drug, doxorubicin (DOX) was enclosed inside of PNPs by physical method. DOX-TNPs were taken up by Trop2-expressing TNBC cells. The release rate of DOX in DOX-TNPs increased rapidly at the intracellular reductive environment due to the cleavage of disulfide bonds. Overall, TNPs showed a potential as a drug carrier for TNBC therapy. |
